Inovio Pharmaceuticals (INO) Given a $13.00 Price Target at HC Wainwright
HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals (NASDAQ:INO) in a research note released on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Other equities analysts also recently issued research reports about the stock. Maxim Group set a $12.00 price objective on shares of Inovio Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, January 2nd. Citigroup started coverage on shares of Inovio Pharmaceuticals in a research note on Friday, October 6th. They set a buy rating and a $10.00 price objective on the stock. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, January 9th. Royal Bank of Canada started coverage on shares of Inovio Pharmaceuticals in a research note on Wednesday, October 18th. They set an outperform rating and a $11.00 price objective on the stock. Finally, BidaskClub downgraded shares of Inovio Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, October 13th. Two analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of Hold and an average price target of $19.16.
Inovio Pharmaceuticals (INO) traded up $0.01 during mid-day trading on Friday, hitting $4.48. 740,900 shares of the stock traded hands, compared to its average volume of 1,290,000. The firm has a market capitalization of $402.72, a price-to-earnings ratio of -3.80 and a beta of 2.74. Inovio Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.15). The business had revenue of $2.60 million during the quarter, compared to analyst estimates of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The firm’s revenue for the quarter was down 79.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.28) earnings per share. analysts predict that Inovio Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of INO. Wasatch Advisors Inc. raised its stake in Inovio Pharmaceuticals by 43.6% during the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after purchasing an additional 793,306 shares during the period. Alyeska Investment Group L.P. purchased a new position in Inovio Pharmaceuticals during the third quarter worth approximately $892,000. GSA Capital Partners LLP purchased a new position in Inovio Pharmaceuticals during the second quarter worth approximately $1,035,000. Vanguard Group Inc. raised its stake in Inovio Pharmaceuticals by 4.2% during the second quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock worth $25,301,000 after purchasing an additional 129,164 shares during the period. Finally, OxFORD Asset Management LLP raised its stake in Inovio Pharmaceuticals by 410.3% during the third quarter. OxFORD Asset Management LLP now owns 126,404 shares of the biopharmaceutical company’s stock worth $799,000 after purchasing an additional 101,633 shares during the period. 32.12% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Inovio Pharmaceuticals (INO) Given a $13.00 Price Target at HC Wainwright” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/inovio-pharmaceuticals-ino-given-a-13-00-price-target-at-hc-wainwright/1808481.html.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.